Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
09:09am, Friday, 03'rd May 2024
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
06:36am, Friday, 03'rd May 2024
Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its e
Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the company
09:28pm, Thursday, 02'nd May 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk pulling back despite strong quarter.
25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway
03:00pm, Thursday, 02'nd May 2024
Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the numbers f
Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
12:21pm, Thursday, 02'nd May 2024
Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Hea
Novo Nordisk faces competitive market: Novasecta
11:34am, Thursday, 02'nd May 2024
Subscribe to CNBC International TV: http://cnb.cx/2wAkfMv Subscribe to CNBC International: http://cnb.cx/2gft82z LinkedIn: https://www.linkedin.com/showcase/cnbc-international/ TikTok: https://www.tik
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
10:26am, Thursday, 02'nd May 2024
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
2 Biotech Stocks To Watch Today Amid Earnings
10:18am, Thursday, 02'nd May 2024
Here are two biotech stocks to watch after their recent earnings report.
Novo Nordisk's Earnings Beat Estimates on Surging Demand for Its Weight-Loss Drugs
08:46am, Thursday, 02'nd May 2024
Novo Nordisk (NVO) reported first-quarter earnings Thursday that beat analysts' estimates as demand surged for its weight loss drugs, Ozempic and Wegovy.
Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1
08:30am, Thursday, 02'nd May 2024
Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said on
Novo Nordisk ups guidance after earnings beat expectations
06:06am, Thursday, 02'nd May 2024
Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. First-quarter sales
Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock's Falling.
05:13am, Thursday, 02'nd May 2024
The Danish pharmaceutical giant, which became Europe's most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy
03:54am, Thursday, 02'nd May 2024
Danish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consume
Novo Nordisk now has more than 130,000 weight-loss prescriptions as it hikes financial outlook
03:53am, Thursday, 02'nd May 2024
Novo Nordisk said its Wegovy injectable drug for weight loss now has more than 130,000 weekly prescriptions in North America alone after boosting supplies to meet insatiable demand.
Earnings report: Novo Nordisk cashes in on weight loss drug fever with better-than-expected results
02:23am, Thursday, 02'nd May 2024
This morning, pharmaceuticals reported triumphant Q1 2024 financial results before markets opened. One of the more memorable highlights was certainly the fact that Novo Nordisk's sales increased by 22
